Hikma Pharmaceuticals Share News (HIK)

Hikma lifts guidance for generics business

(Sharecast News) - Hikma Pharmaceuticals lifted annual revenue and margin guidance for its generics business as first-half core operating profit rose 35%.

UK earnings, trading statements calendar - next 7 days

Commodity-heavy FTSE 100 lifted by Anglo American, China stimulus hopes

Anglo American shines after production update

*

Hikma, Fresenius shares rally after tornado hits rival Pfizer's U.S. plant

LONDON, July 20 (Reuters) - Shares in UK pharmaceutical company Hikma rose by the most in 10 months on Thursday after tornado damage to a U.S. facility owned by competitor Pfizer boosted other drugmakers' stock.

Shares in Pfizer rivals Hikma, Fresenius rally after tornado hits factory

LONDON, July 20 (Reuters) - Shares in UK pharmaceutical company Hikma rose by the most in 10 months on Thursday, hitting an 18-month high, following news of tornado damage to a U.S. facility owned by competitor Pfizer, which boosted other drugmakers' stock.

Hikma surges after tornado damages Pfizer injectables plant

(Sharecast News) - Hikma Pharmaceuticals surged on Thursday, with traders pointing to news that a major Pfizer injectables plant in North Carolina was hit by a tornado and heavily damaged on Wednesday.

LONDON BROKER RATINGS: UBS raises AstraZeneca; RBC cuts Bunzl

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Director dealings: Hikma non-exec invests, LSE Group share buyback rolls on

(Sharecast News) - Hikma Pharmaceuticals was among those on the list of director buys on Thursday, after a non-executive director added almost £27k worth of shares to his holding.

LONDON BROKER RATINGS: Citigroup cuts Sainsbury to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

LONDON BROKER RATINGS: RBC raises Intertek; Davy likes Greencoat UK

(Alliance News) - The following London-listed shares received analyst recommendations xxxxday morning:

Broker tips: HSBC, Hikma, Pearson

(Sharecast News) - Berenberg upgraded HSBC to 'buy' from 'hold' on Wednesday, keeping the price target at 780p, as it said the bank's return on tangible equity of around 13% and attractive growth potential are undervalued.

RBC Capital lifts Hikma price target, reiterates 'outperform'

(Sharecast News) - RBC Capital Markets lifted its price target on Hikma Pharmaceuticals on Wednesday to 2,050p from 1,950p as it reiterated its 'outperform' rating.

LONDON BROKER RATINGS: DZ Bank cuts BP to 'hold'; Berenberg likes HSBC

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

UK dividends calendar - next 7 days

Hikma upgrades full-year guidance in response to Generics unit growth

(Alliance News) - Hikma Pharmaceuticals PLC on Friday upgraded its 2023 financial guidance following a stronger than expected start to the year in its Generics business.